NEW YORK, NY (Feb. 26, 2026)--CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers.
CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
The global cell and gene therapy market is forecast to surge from $10.4 billion to more than $45 billion by 2035, with over 40 FDA-approved products and North America commandi ...
B-cell lymphomas constitute a heterogeneous group of malignancies derived from B-lymphocytes, with diffuse large B-cell lymphoma (DLBCL) representing the most common subtype. Among these, double-hit ...
Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results